

PERSONAL INFORMATION **Anna Sundlov**WORK EXPERIENCE

January 2019- Present

Researcher

Lund University (Sweden)

Supervision of PhD-students in different research projects.

April 2010-March 2021

Senior Consultant in Oncology

Skåne University Hospital (Sweden)

Head of the Unit for Endocrine Tumors and Radionuclide Therapy

October 2018-March 2021

Founder and Senior Consultant

Synapticon AB (Sweden)

Consulting services for small and medium-sized pharmaceutical companies, CROs, academic research groups and others who need part-time or project-based consultation in designing clinical trials, medical writing, medical monitoring or training in any of the areas of expertise (oncology, radionuclide therapy, clinical trials).

July 2006-May 2009

Medical Advisor

Novartis Oncology (Spain)

Responsible for the internal and external scientific advice. Management on a national level of international clinical trials phase I-IV including critical protocol review, feasibility feed-back, site selection, lead investigator meetings, negotiations with cooperative groups and CROs, initiate action plans, etc.

July 2001-June 2006

Resident physician Medical Oncology

La Paz University Hospital (Spain)

EDUCATION AND TRAINING

August 2012-February 2020

PhD

Lund University (Sweden)

PhD thesis entitled Tailoring Radionuclide Therapy of Neuroendocrine Tumors

July 2001-June 2006

Specialist in Oncology

La Paz University Hospital (Spain)

January 1992-October 1998

Medical Degree in Medicine and Surgery

Karolinska Institutet (Sweden)

ADDITIONAL INFORMATION

Expertise

I have over a decade of clinical experience in using radiopharmaceuticals (aka radionuclide therapy) for the treatment of different types of cancer.

I am active in academic research in the area of using individualized dosimetry to personalize radionuclide therapy in different indications.

During the same time period I have also specialized in the treatment of patients with different types of endocrine tumors, e.g. thyroid cancer, neuroendocrine tumors, pheochromocytoma, paraganglioma, adrenocortical cancer, merkel cell carcinoma, among others.

Ever since I started my specialist training in 2001 I have been involved in clinical trials as sub-investigator or principal investigator in phase I-III pharma-sponsored trials, and sponsor and/or PI in uni- and multicenter academic clinical trials.

- Publications** The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
Venizelos, A., Elvebakken, H., Perren, A., Nikolaienko, O., Deng, W., Lothe, I. M. B., Couvelard, A., Hjortland, G. O., Sundlov, A., Svensson, J. B., Garresori, H., Kersten, C., Hofslie, E., Detlefsen, S., Krogh, M., Sorbye, H. & Knappskog, S., 2021 Oct 1, (E-pub ahead of print) In: *Endocrine-Related Cancer*.
- Impact of Specific Bowel Symptoms on Quality of Life in Patients with Midgut Neuroendocrine Tumours
Ohlsson, H., Wahlberg, G., Malmstrom, M., Gustafsson, R., Sundlov, A., Nordenstrom, E. & Almquist, M., 2021 May 9, (E-pub ahead of print) In: *World Journal of Surgery*.
- Peptide Receptor Radionuclide Therapy - Prospects for Personalised Treatment
Sundlov, A. & Sjogreen-Gleisner, K., 2021 Feb 1, In: *Clinical Oncology*. 33, 2, p. 92-97 6 p.
- Dosimetric quantities of neuroendocrine tumors over treatment cycles with ¹⁷⁷Lu-DOTA-TATE
Roth, D., Gustafsson, J., Warfvinge, C. F., Sundlov, A., Akesson, A., Tennvall, J. & Sjogreen Gleisner, K., 2021, (E-pub ahead of print) In: *Journal of Nuclear Medicine*. 62, 10
- Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms
Pommergaard, H. C., Nielsen, K., Sorbye, H., Federspiel, B., Tabaksblat, E. M., Vestermark, L. W., Janson, E. T., Hansen, C. P., Ladekarl, M., Garresori, H., Hjortland, G. O., Sundlov, A., Galleberg, R., Knigge, P., Kjaer, A., Langer, S. W. & Knigge, U., 2021, (E-pub ahead of print) In: *Journal of Neuroendocrinology*.
- Pituitary function after high-dose ¹⁷⁷Lu-DOTATATE therapy and long-term follow-up
Sundlov, A., Sjogreen-Gleisner, K., Tennvall, J., Dahl, L., Svensson, J., Akesson, A., Bernhardt, P. & Lindgren, O., 2020 Apr 8, (E-pub ahead of print) In: *Neuroendocrinology*.
- Characterisation of a hand-held CZT-based gamma camera for ¹⁷⁷Lu imaging
Roth, D., Larsson, E., Sundlov, A. & Sjogreen Gleisner, K., 2020, In: *EJNMMI Physics*. 7, 1, 46.
- Tailoring Radionuclide Therapy of Neuroendocrine Tumors - Bridging the Gaps
Sundlov, A., 2020, Lund: Lund University, Faculty of Medicine. 97 p.
- A prospective observational study to evaluate the effects of long-acting somatostatin analogs on ⁶⁸Ga-DOTATATE uptake in patients with neuroendocrine tumors
Galne, A., Almquist, H., Almquist, M., Hindorf, C., Ohlsson, T., Nordenstrom, E., Sundlov, A. & Tragardh, E., 2019, In: *Journal of Nuclear Medicine*. 60, 12, p. 1717-1723
- Bone marrow absorbed doses and correlations with hematological response during ¹⁷⁷Lu-DOTATATE treatments are influenced by image-based dosimetry method and presence of skeletal metastases
Hagmarker, L., Svensson, J., Ryden, T., van Essen, M., Sundlov, A., Sjogreen Gleisner, K., Gjertsson, P. & Bernhardt, P., 2019, In: *Journal of Nuclear Medicine*. 60, 10, p. 1406-1413
- The Effect of Radioiodine Treatment on TRAb, Anti-TPO, and Anti-TG in Graves' Disease
Lindgren, O., Asp, P., Sundlov, A., Tennvall, J., Shahida, B., Planck, T., Asman, P. & Lantz, M., 2019, In: *European Thyroid Journal*. 8, 2, p. 64-69
- Feasibility of simplifying renal dosimetry in ¹⁷⁷Lu peptide receptor radionuclide therapy
Sundlov, A., Gustafsson, J., Brolin, G., Mortensen, N., Hermann, R., Bernhardt, P., Svensson, J., Ljungberg, M., Tennvall, J. & Sjogreen Gleisner, K., 2018 Dec 1, In: *EJNMMI Physics*. 5, 1, 12.
- Quantitative analysis of phantom studies of ¹¹¹In and ⁶⁸Ga imaging of neuroendocrine tumours
Jonsson, L., Stenvall, A., Mattsson, E., Larsson, E., Sundlov, A., Ohlsson, T. & Hindorf, C., 2018 Dec 1, In: *EJNMMI Physics*. 5, 1, 5.
- A method for tumor dosimetry based on hybrid planar-SPECT/CT images and semiautomatic segmentation
Roth, D., Gustafsson, J., Sundlov, A. & Sjogreen Gleisner, K., 2018 Nov, In: *Medical Physics*. 45, 11, p. 5004-5018
- Health-Related Quality of Life After Surgery for Small Intestinal Neuroendocrine Tumours
Milanetto, A. C., Nordenstrom, E., Sundlov, A. & Almquist, M., 2018, In: *World Journal of Surgery*. 42, 10, p. 3231-3239
- SPECT image segmentation for estimation of tumour volume and activity concentration in ¹⁷⁷Lu-DOTATATE radionuclide therapy

Gustafsson, J., Sundlov, A. & Sjogreen Gleisner, K., 2017 Dec 1, In: EJMNM Research. 7, 1, 18.

Individualised ¹⁷⁷Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry

Sundlov, A., Sjogreen-Gleisner, K., Svensson, J., Ljungberg, M., Olsson, T. G., Bernhardt, P. & Tennvall, J., 2017, In: European Journal of Nuclear Medicine and Molecular Imaging. 44, 9, p. 1480-1489

Long-term retention of ¹⁷⁷Lu/^{177m}Lu-Dotatate in patients investigated by gamma spectrometry and gamma camera imaging.

Sjogreen Gleisner, K., Brolin, G., Sundlov, A., Mjekiqi, E., Ostlund, K., Tennvall, J. & Larsson, E., 2015, In: Journal of Nuclear Medicine. 56, 7, p. 976-984

Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms

Janson, E. T., Sorbye, H., Welin, S., Federspiel, B., Gronbaek, H., Hellman, P., Ladekarl, M., Langer, S. W., Mortensen, J., Schalin-Jantti, C., Sundin, A., Sundlov, A., Thiis-Evensen, E. & Knigge, U., 2014, In: Acta Oncologica. 53, 10, p. 1284-1297

The role of RANK-ligand inhibition in cancer: the story of denosumab

Castellano, D., Sepulveda, J. M., Garcia-Escobar, I., Rodriguez-Antolin, A., Sundlov, A. & Cortes-Funes, H., 2011, In: The Oncologist. 16, 2, p. 136-45

Bacteriemia por *Acinetobacter ursingii*

Romero-Gomez, M. P., Sundlov, A., Saez-Nieto, J. A., Alvarez, D. & Pena, P., 2006, In: Enfermedades Infecciosas y Microbiologia Clinica. 24, 8, p. 535-536 2 p.

Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer

Feliu, J., Martin, G., Castro, J., Sundlov, A., Rodriguez-Jaraiz, A., Casado, E., Lomas, M., Madronal, C., Galan, A., Belda, C. & Gonzalez-Baron, M., 2006, In: Cancer Chemotherapy and Pharmacology. 58, 4, p. 527-531 5 p.

Treatment options for colorectal cancer in the elderly

Feliu, J., Castro, J., Belda, C., Sundlov, A., Casado, E. & Gonzalez-Baron, M., 2006, In: Aging and Mental Health. 2, 6, p. 931-942 12 p.

Anticuerpos contra el cancer

Barriuso Feijoo, J., Sundlov, A. & Gonzalez Baron, M., 2004, In: Revista Clinica Espanola. 204, 12, p. 649-654 6 p.

Projects

CLINICAL TRIALS AS PRINCIPAL INVESTIGATOR

VISION - an international, prospective, open-label, multicenter, randomized phase 3 study of ¹⁷⁷Lu-PSMA-617 in the treatment of patients with progressive psma-positive metastatic castration-resistant prostate cancer (mCRPC)

BAY 2287411 - First-in-human phase I trial of a thorium-227 labeled antibody-chelator conjugate, in patients with tumors known to express mesothelin

ILUMINET - an academic phase II trial of safety and efficacy of Lu¹⁷⁷-DOTATATE treatment of neuroendocrine tumors

GAPETTO - an academic, prospective trial on the use of Ga⁶⁸-DOTATATE-PET in patients with neuroendocrine tumors

BASKET - a phase II trial in a selected number of solid tumors to investigate safety and efficacy of lurbnectidine

COOPERATE-2 - an international randomized phase II trial of safety and efficacy of everolimus +/- pasireotide in patients with pancreatic neuroendocrine tumors

LUNA - an international randomized phase II trial of safety and efficacy of everolimus +/- pasireotide in patients with carcinoid tumors of the lung and thymus

NORDIC GI-NEC - a Nordic collaborative prospective registry study of the treatment of gastrointestinal neuroendocrine carcinomas

ET-NEC - a Nordic collaborative prospective trial of everolimus in combination with temozolomide in advanced/metastatic gastrointestinal neuroendocrine carcinoma

.....

CLINICAL TRIALS AS SUB-INVESTIGATOR

EXAMINER -an international phase III trial of cabozantinib in medullary thyroid cancer

TELESTAR -Telotristat Etiprate for Somatostatin analogue refractory carcinoid syndrome

SELECT - an international, randomised phase III trial of lenvatinib in iodine-refractory differentiated thyroid cancer

ALFARADIN - Ra223 for the treatment of castration resistant prostate cancer with bone metastasis

ASTRA - a randomised, double-blind, placebo-controlled study comparing selumetinib plus radioiodine vs radioiodine alone in patients with newly diagnosed high-risk differentiated thyroid cancer

DECISION - an international, randomised, phase III trial of sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer

.....

CLINICAL TRIALS Author/ co-author

START-NET - Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. An open-label, multi-center, randomized controlled trial comparing safety and efficacy of personalized vs non-personalized radionuclide therapy with ¹⁷⁷Lu-DOTATOC

NORDIC ET-NEC - A Nordic collaborative prospective trial of everolimus in combination with temozolomide in advanced/metastatic gastrointestinal neuroendocrine carcinoma

ILUMINET - an academic phase II trial of safety and efficacy of Lu177-DOTATATE treatment of neuroendocrine tumors

GAPETTO - an academic, prospective trial on the use of Ga68-DOTATATE-PET in patients with neuroendocrine tumors

RAPTOR - Open-label phase II trial of everolimus monotherapy for patients with advanced papillary renal cell cancer

Memberships Member of the European Neuroendocrine Tumor Society (ENETS)
Member of the European Association of Nuclear Medicine (EANM)

Other Relevant Information